Skip to main content
Caplight Logo









invIOs GmbH

invIOs GmbH

Private
ViennaHealthcare & Life Scienceshttps://www.invios.com/

Last Round

Series A

Oct 15, 2024

Total Funding Raised

$8.94M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

invIOs GmbH is a biotechnology company that develops next-generation cancer immunotherapies using its proprietary EPiC cell therapy platform.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine

Business Model

B2B

Customer Profile

Data as a Service, Services & Consulting

AI Layer

Non-AI

Keywords

cell therapyimmuno-oncologycancer immunotherapyautologous cell therapysolid tumor treatmentRNA interferenceCAR T-cell therapybiotech R&Dprecision medicinedrug discoveryclinical-stage biotechpersonalized medicinenext-gen immunotherapycheckpoint inhibitormRNA therapy

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

invIOs GmbH Comparables

Compare invIOs GmbH with similar companies based on industry and business-model similarity.

invIOs GmbH comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
HotSpot Therapeutics
68%
Adaptimmune Therapeutics
68%
Nurix Therapeutics, Inc.
68%

invIOs GmbH Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AOct 15, 2024

Key People

Founding team and executive leadership

Andreas Gerber

Chief Operating Officer

Executive Team

invIOs GmbH Investors

Notable investors and investment history

invIOs GmbH investors
InvestorRounds
Ligand PharmaceuticalsSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors increased 315% MoM.

  • Jul 25, 2026

    Monthly visitors increased 1667% MoM, from 36 to 636.

invIOs GmbH Filings

Explore SEC and related filing metadata, where available.

invIOs GmbH filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about invIOs GmbH's valuation, stock price, and market status.

Is invIOs GmbH a public or private company?

invIOs GmbH is a private company.

What is the current stock price of invIOs GmbH?

invIOs GmbH is a private company with no public stock price. No recent secondary market data is available.

How much is invIOs GmbH worth (valuation)?

Valuation information for invIOs GmbH is not publicly available.

Can I buy invIOs GmbH stock?

invIOs GmbH shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was invIOs GmbH's last funding round?

invIOs GmbH's most recent funding round was Series A on October 15, 2024.

Who are the main investors in invIOs GmbH?

Key investors in invIOs GmbH include Ligand Pharmaceuticals.

Will invIOs GmbH IPO soon?

No public IPO plans have been announced for invIOs GmbH.

How can I track invIOs GmbH secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor invIOs GmbH's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersVienna
Employee Range13
Year Founded2022
Last FundingOct 15, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?